NASDAQ:TMDX
TransMedics Group, Inc.
TransMedics Group, Inc.'s revenue grew 37.1% in fiscal 2025 to $605.5M while operating margin rose to 17.9%, its highest in 8 years. Free cash flow was $133.6M, 22.1% of revenue, and the diluted share count rose 15.1%.Summary generated from TransMedics Group, Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$605.5M
Revenue growth+37.1%
Revenue, 5-yr CAGR+88.2%
Gross margin59.9%
Operating margin17.9%
Net margin31.4%
ROICn/a
Return on equity54.2%
Debt / equityn/a
Free cash flow$133.6M
FCF margin22.1%
Share count change+15.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 30 | 93 | 242 | 442 | 605 |
| Operating income | −39 | −31 | −29 | 37 | 109 |
| Net income | −44 | −36 | −25 | 35 | 190 |
| Free cash flow | −32 | −58 | −165 | −81 | 134 |
Recent filings
- 4Insider transaction report
Sep 14, 2026 - 8-KDirector or officer change
Sep 10, 2026 - 4Insider transaction report
Aug 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KResults of a shareholder vote
May 21, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 5, 2026 - 8-KResults of operations and financial condition
May 5, 2026